Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

11 trials with published results (14%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

2.6%

2 terminated out of 76 trials

Success Rate

92.0%

+5.5% vs benchmark

Late-Stage Pipeline

14%

11 trials in Phase 3/4

Results Transparency

48%

11 of 23 completed with results

Key Signals

11 with results92% success

Data Visualizations

Phase Distribution

61Total
Not Applicable (13)
Early P 1 (2)
P 1 (11)
P 2 (24)
P 3 (10)
P 4 (1)

Trial Status

Completed23
Recruiting22
Unknown12
Active Not Recruiting10
Withdrawn3
Not Yet Recruiting3

Trial Success Rate

92.0%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (76)

Showing 20 of 20 trials
NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT01366144Phase 1Active Not Recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT04607590Not ApplicableActive Not RecruitingPrimary

Yoga Program for Improving the Quality of Life in Couples Coping With Cancer

NCT06995898Not ApplicableRecruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT07118176Phase 1Active Not Recruiting

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT07283939Not ApplicableRecruiting

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

NCT07309991RecruitingPrimary

Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy

NCT00991094Recruiting

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

NCT06265285Phase 2Recruiting

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

NCT06872515Not ApplicableRecruiting

Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)

NCT06067438Phase 2Recruiting

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

NCT07596654RecruitingPrimary

The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer

NCT06549413Active Not RecruitingPrimary

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

NCT04314401Active Not Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

NCT07000253Phase 2Recruiting

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

NCT06712706Active Not Recruiting

Effect of Feeding Jejunostomy on Sarcopenia in Patients With Esophageal Cancer

NCT06964568Phase 3RecruitingPrimary

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

NCT03948100Not ApplicableRecruitingPrimary

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

NCT07416825Not ApplicableCompleted

Inter-Observer Delineation Differences in Esophageal Cancer GTV on MR, CT, and PET/CT Protokol šečerov Ermenc 28dec19

NCT05775939Not ApplicableRecruiting

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Scroll to load more

Research Network

Activity Timeline